An interventional study of TAVR in Aortic Stenosis, sponsored by Peijia Medical Technology (Suzhou) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Peijia Medical Technology (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment
Among 67 studies in Aortic Valve Stenosis with a site in China — 41 open to participants now, 49 under way, 3 of them phase 3. Aortic Valve Stenosis · China.
Among the 67 studies in Aortic Valve Stenosis with a site in China, this one is the 17th largest by enrollment of the 47 interventional ones, is one of 7 that started in 2021, is one of 37 with no phase, reaches primary completion later than 9 of the 48 other live ones, and was the 67th registered.
1,025 studies on the registry are indexed under Aortic Valve Stenosis; 293 are open to participants now.
This study's enrollment of 150 is above the median of 126 across 554 interventional studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →41 of the 67 studies in Aortic Valve Stenosis with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →67 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 7 started in 2021.
Median enrollment 120 across the 47 interventional studies, 465 across the 20 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
27 of 67 have an industry lead sponsor. The 10 most frequent:
Peijia Medical Technology (Suzhou) Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Peijia Medical Technology (Suzhou) Co., Ltd. has 4 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07335900RenJi HospitalA Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis | 2026-12-30 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT06891079Xijing HospitalVideodensitometric Angiographic Assessment of AR in the Cath-lab for Intraprocedural Guidance of TAVI in CHINA | 2026-12-31 |
| NCT07035847Chinese Academy of Medical Sciences, Fuwai HospitalTransaxillary TAVR With Solely Echocardiography Guidance | 2026-12-31 |
| NCT07414342Beijing Balance Medical Technology Co., LtdSafety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis | 2027-09 |
Among the 67 studies in Aortic Valve Stenosis with a site in China, from their registry updates:
To evaluate the safety and effectiveness of the TaurusNXT™ transcatheter aortic valve system in a patient population with symptomatic severe AS requiring replacement/repair of their native aortic valve that are at high risk for open surgical aortic valve replacement/repair (SAVR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: TAVR
TAVR usingTaurusNXT® transcatheter aortic valve system
All-cause mortality at 12 months
All-cause mortality
Time frame: 1 year
Device Success
Vascular access, delivery and deployment of the prosthetic aortic valve were successful, and the delivery system was successfully withdrawn. A prosthetic aortic valve was accurately implanted in the anatomical position. The prosthetic aortic valve met the expected requirements (mean transaortic pressure gradient \< 20 mmHg or transaortic flow velocity \< 3 m/s; no moderate or greater prosthetic aortic regurgitation or paravalvular leakage).
Time frame: immediately after the procedure
Procedural Success
device success with no occurrence of death, disabling stroke, myocardial infarction, or conversion to surgery within 72 hours post-procedure or before discharge
Time frame: Perioperative/Periprocedural
Improvement in cardiac function (NYHA functional class)
Time frame: 1 year
Postoperative quality of life of subjects (EuroQol five-dimension questionnaire [EQ-5D] visual analogue scale [VAS] score)
The EuroQol five-dimension questionnaire (EQ-5D) visual analogue scale (VAS) score ranges from 0 to 100, with higher scores indicating a better self-rated health state.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Feb 2024, 29 months.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 29 months is close to that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peijia Medical Technology (Suzhou) Co., Ltd.